Published in Mol Carcinog on August 01, 1999
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) (2010) 1.91
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A (2002) 1.61
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia (2001) 1.32
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia (2008) 1.24
Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog (2007) 1.24
Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A (2001) 1.21
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.20
NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. FASEB J (2008) 1.12
Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res (2008) 1.10
Molecular mechanisms of mouse skin tumor promotion. Cancers (Basel) (2010) 1.09
Inhibition of photocarcinogenesis by platelet-activating factor or serotonin receptor antagonists. Cancer Res (2008) 1.09
Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol (2009) 1.07
The use of animal models for cancer chemoprevention drug development. Semin Oncol (2010) 1.05
Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect (2006) 1.04
Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol (2010) 1.03
Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity. Biochem Pharmacol (2010) 1.03
The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev (2011) 0.99
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res (Phila) (2009) 0.98
Sunlight and skin cancer: lessons from the immune system. Mol Carcinog (2007) 0.95
Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer (2010) 0.95
Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma. Carcinogenesis (2012) 0.93
The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome. Cancer Prev Res (Phila) (2013) 0.92
Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci (2009) 0.91
E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol (2006) 0.91
Cox-2 gene expression in chemically induced skin papillomas cannot predict subsequent tumor fate. Mol Oncol (2010) 0.90
Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation. Genes Dis (2014) 0.90
Cyclooxygenase 2 expression in pterygium. Mol Vis (2007) 0.89
Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol (2010) 0.89
UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression. Cancer Prev Res (Phila) (2010) 0.87
Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am J Pathol (2008) 0.86
Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention. J Invest Dermatol (2014) 0.86
Effect of suppressive oligodeoxynucleotides on the development of inflammation-induced papillomas. Cancer Prev Res (Phila) (2011) 0.86
Study of the expression of CD30 in pterygia compared to healthy conjunctivas. Mol Vis (2009) 0.85
Fernblock, a nutriceutical with photoprotective properties and potential preventive agent for skin photoaging and photoinduced skin cancers. Int J Mol Sci (2011) 0.84
Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression. Am J Pathol (2002) 0.84
Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study. Int J Cancer (2011) 0.83
Cyclooxygenase-2 (COX-2) mediates arsenite inhibition of UVB-induced cellular apoptosis in mouse epidermal Cl41 cells. Curr Cancer Drug Targets (2012) 0.82
The Role of Macrophage Migration Inhibitory Factor (MIF) in Ultraviolet Radiation-Induced Carcinogenesis. Cancers (Basel) (2010) 0.82
Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans. Biochem Pharmacol (2013) 0.81
Baicalein inhibits DMBA/TPA-induced skin tumorigenesis in mice by modulating proliferation, apoptosis, and inflammation. Inflammation (2013) 0.81
Chemoprevention strategies in the prostate: an overview. Rev Urol (2002) 0.81
Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation. Carcinogenesis (2012) 0.81
Topical application of thymidine dinucleotide to newborn mice reduces and delays development of UV-induced melanomas. J Invest Dermatol (2012) 0.81
Promising agents for chemoprevention of skin cancer. Curr Oncol (2006) 0.80
The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors. Mol Carcinog (2011) 0.80
MLK3 is a novel target of dehydroglyasperin D for the reduction in UVB-induced COX-2 expression in vitro and in vivo. J Cell Mol Med (2014) 0.79
The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin. Mol Oncol (2014) 0.79
UVB light upregulates prostaglandin synthases and prostaglandin receptors in mouse keratinocytes. Toxicol Appl Pharmacol (2008) 0.79
Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands. Mol Carcinog (2011) 0.79
Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis. PLoS One (2013) 0.79
The inhibitory effect of a novel polypeptide fraction from Arca subcrenata on cancer-related inflammation in human cervical cancer HeLa cells. ScientificWorldJournal (2014) 0.78
The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1. Neoplasia (2001) 0.78
Tumor-promoting role of TGFβ1 signaling in ultraviolet B-induced skin carcinogenesis is associated with cutaneous inflammation and lymph node migration of dermal dendritic cells. Carcinogenesis (2013) 0.78
Ultraviolet light exposure stimulates HMGB1 release by keratinocytes. Arch Dermatol Res (2013) 0.77
Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis. Carcinogenesis (2014) 0.77
Cell-type-specific roles for COX-2 in UVB-induced skin cancer. Carcinogenesis (2014) 0.76
New agents for prevention of ultraviolet-induced nonmelanoma skin cancer. Semin Cutan Med Surg (2011) 0.76
Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy. Cancer Prev Res (Phila) (2015) 0.76
Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer. Mol Cancer Res (2014) 0.76
Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis. Dermatol Ther (Heidelb) (2017) 0.75
Functional similarity between E6 proteins of cutaneous human papillomaviruses and the adenovirus E1A tumor-restraining module. J Virol (2013) 0.75
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1997) 5.11
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A (1994) 4.15
Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A (1993) 3.93
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem (1990) 3.34
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res (1998) 3.11
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71
Localization of avian tumor virus group-specific antigen in cell and virus. Virology (1966) 2.70
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest (1990) 2.66
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A (1992) 2.55
The group-specific antigen and other structural proteins of hamster and mouse C-type viruses. Virology (1971) 2.46
Induction of cyclin D1 overexpression by activated ras. Oncogene (1994) 2.35
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med (1996) 2.28
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res (2000) 2.12
Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. Proc Natl Acad Sci U S A (1998) 2.10
Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (1998) 2.03
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res (2000) 1.96
Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev (1998) 1.88
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res (2000) 1.88
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res (2000) 1.84
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem (2000) 1.84
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res (1996) 1.77
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J (1995) 1.74
Hamster-tropic sarcomagenic and nonsarcomagenic viruses derived from hamster tumors induced by the Gross pseudotype of Moloney sarcoma virus. Proc Natl Acad Sci U S A (1970) 1.71
Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr (2000) 1.69
Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J (1999) 1.64
A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev (1994) 1.64
Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst (1999) 1.64
VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene (1998) 1.61
A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem (1996) 1.61
Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol (1991) 1.59
Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest (1994) 1.59
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res (1996) 1.58
High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature (1995) 1.57
Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst (1990) 1.56
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A (2000) 1.54
p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst (1993) 1.54
Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest (1997) 1.54
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (1993) 1.54
Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci U S A (1996) 1.51
Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev (1999) 1.49
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res (1995) 1.48
Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA (1995) 1.47
Studies on the bronchial counterpart of the Kultschitzky (argentaffin) cell and innervation of bronchial glands. J Ultrastruct Res (1965) 1.46
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol (1999) 1.46
Implantable cardioverter defibrillator utilization among device recipients presenting exclusively with syncope or near-syncope. J Cardiovasc Electrophysiol (1997) 1.42
Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst (1997) 1.40
Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum. Clin Chem (2001) 1.40
Measurement of total carbon dioxide production by means of D2O18. 1955. Obes Res (1997) 1.39
Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci U S A (1981) 1.38
Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A (1998) 1.38
Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol (1995) 1.37
Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res (1995) 1.36
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest (1995) 1.33
Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res (1999) 1.30
E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol (1999) 1.29
Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med (1981) 1.29
Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys (1985) 1.28
Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat Genet (2001) 1.28
Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene (1998) 1.25
Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res (1992) 1.25
COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci (1999) 1.25
(C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci U S A (1994) 1.24
Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res (1994) 1.23
High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst (1991) 1.23
Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res (1987) 1.23
Effects of sublethal gamma radiation on T and B cell activity in the antibody response of mice. Radiat Res (1976) 1.23
Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene (1993) 1.22
Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors. Proc Natl Acad Sci U S A (1990) 1.20
Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy. Proc Natl Acad Sci U S A (1987) 1.19
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther (1997) 1.18
Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ (1996) 1.15
Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res (1993) 1.15
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 1.14
Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis (1995) 1.14
The effects of long chain free fatty acids on human neutrophil function and structure. Lab Invest (1976) 1.13
Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res (1996) 1.13
ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Mol Carcinog (1999) 1.12
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther (1994) 1.12
Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer (1980) 1.12
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res (2000) 1.12
A variant of pulmonary alveolar microlithiasis in nackt mice. Vet Pathol (2002) 1.11
Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res (1999) 1.10
Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. Carcinogenesis (2001) 1.10
Radioisotopic "subtraction" scanning for pancreatic lesions. Radiology (1967) 1.09
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev (1997) 1.09
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am (1996) 1.08
A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res (2000) 1.07